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The recent launch of the new National elite women’s football competitions in Australia
has seen a 20–50% increase in grassroots female participation. With the growing
participation across grassroots to elite competitions, understanding the health of female
athletes should be prioritized. In elite level athletes, hormonal contraceptive (HC) use is
common (∼50%), however, little is known about the prevalence and reasons for use and
disuse of HC in elite female football athletes. As such, the impact of HC use is often
not considered when monitoring the health of female footballers. This study involved a
subset of data collected as part of a larger questionnaire investigating menstrual cycle
function, hormonal contraception use, and the interaction with training load volume and
perceived performance in elite female football code athletes. A total of 177 participants
completed the questionnaire across three football codes within Australia (rugby league,
rugby union/sevens, Australian football). One third (n = 58) of athletes were currently
using HC, predominately in the form of an oral contraceptive pill (OC, n = 47). Reasons
for use included: to avoid pregnancy (71%); to control/regulate cycle (38%); and to
reduce menstrual pain (36%). However, most athletes using an OC (89%) could not
identify the type of pill used (e.g., mono-, bi-, or triphasic). The main reason for disuse
was due to the negative side effects (n = 23), such as mood swings, weight gain,
and depression/anxiety. Comparing HC users and non-users, there were no statistical
differences in the number of reported menstrual symptoms, use of medication to relieve
menstrual pain, or frequency for needing to adapt training due to their menstrual cycle
(p > 0.05). Since most athletes were unaware of the type of OC they used, female
football athletes require further education about the different types of HC, and specifically
OC, available to them. Similarities in the symptoms experienced, pain management,
and training adaptation requirements between groups suggests that HC use may not
have the intended outcome for certain athletes. As such, greater awareness of athlete’s
personal experiences with the menstrual cycle, how HC may influence their experience,
and acknowledgment of non-pharmacological methods to help manage menstrual cycle
related symptoms are warranted.
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INTRODUCTION
Monitoring the menstrual cycle for athlete’s optimal health and
performance is now recognized as an important aspect of female
sport (Harber, 2011). A recent meta-analysis looking at the
influence of menstrual cycle phase on exercise performance
highlights the challenges in clearly identifying this relationship
due to poor quality studies and variation in study design
(McNulty et al., 2020). Given these challenges, it is recommended
that individualized approaches to managing an athletes’ training
across their menstrual cycle be taken (McNulty et al., 2020).
While research is inconclusive as to whether menstrual cycle
phase affects performance, many athletes report negative
symptoms and feel that they perform worse at certain phases of
their cycle (Armour et al., 2020). To alleviate these symptoms,
oral contraceptive (OC) use has been reported as common
practice among athletes (Schaumberg et al., 2018).
Understanding the prevalence of hormonal contraceptive
(HC) use and their reasons for use/disuse are important
for practitioners to develop appropriate monitoring and
management practices for female athletes. Approximately 50% of
elite British athletes use HC (Martin et al., 2018), while similar
values are reported in elite Australian athletes (47%, Larsen et al.,
2020). In recreational to elite level Australian athletes, the use of
HC use is slightly lower at ∼40% (Armour et al., 2020), likely
due to the inclusion of recreational level participants. Despite
the advantages of using HC to control their menstrual cycle
and potentially reduce menstrual-related symptoms, evidence
suggests potential negative outcomes associated with HC use
such as a higher risk for depression (Anderl et al., 2020), lower
bone mineral density (Allaway et al., 2020), and greater oxidative
stress (Cauci et al., 2016), particularly with OC methods.
Understanding the reasons why athletes use HC is important to
inform athletes’ decision to start, stop, or switch between different
HC options.
The number of elite women’s National-level competitions,
specifically within the football codes of Australian football,
rugby union, and rugby league has increased over the past
10 years. While these athletes are considered to be playing at
the top-level of competition for their sport, given the infancy
of these competitions, little research is available on these
athletes to inform athlete management practices. Additionally,
most research regarding the menstrual cycle and hormonal
contraceptive use to date has been conducted on the general
population (Schaumberg et al., 2018;Mackay et al., 2019; Freemas
et al., 2020) or endurance athletes (Redman and Weatherby,
2004; Solli et al., 2020). Further research is therefore necessary
to report the prevalence and reasons for HC use within
female football codes to help shape athletes’ management and
monitoring practices. The aim of this study was to determine
the prevalence and reasons for HC use in athletes competing in
female football codes in Australia.
MATERIALS AND METHODS
Questionnaire Design
The data used in this study are a subset from a larger
questionnaire completed between September 2019 and May
2020, hosted on Qualtrics and adapted from previously used
menstrual cycle questionnaires (Armour et al., 2020; Bruinvels
et al., 2020). The larger questionnaire gathered data from six
areas; sporting background, menstrual cycle function, medical
history, hormonal contraceptive use, the interaction between
training loads and the menstrual cycle, and education and
communication practices regarding the menstrual cycle. This
study primarily used data from the HC use section, sporting
background (for participant characteristics), and questions
regarding menstrual-related symptoms, use of medication to
alleviate symptoms, and the need to adapt training. All questions
used within this study were multiple choice answers, with some
questions allowing an option for “Other, please specify.” This
project was approved by the La Trobe University Human Ethics
committee (HEC19066). Participants provided informed consent
and the questionnaire was conducted anonymously.
Recruitment Strategy
Participants were eligible to complete the survey if they were
currently competing in a female football code at a representative
level and were 16 years of age or over at the time of completing
the survey. National sporting bodies were contacted via email
and asked to distribute the survey to their player network.
The following sporting bodies approved the questionnaire to
be disseminated to their state and national representative
players: Australian Football League, Rugby Australia, National
Rugby League.
Within Australia, there are an estimated 420 elite female
Australian football players, 90 elite rugby league players, 100 elite
rugby union players, and 150 elite rugby sevens players (although
some athletes may play in both rugby union and rugby sevens
competitions, and so the total number of elite athletes across both
sports is likely lower). To be considered a representative sample,
the aim was for a minimum 20% response rate within each sport.
Statistical Analysis
Descriptive statistics are presented as mean (standard deviation)
for normally distributed data and counts and proportions (%)
for categorical data. Chi-squared analysis was used to compare
responses between hormonal contraceptive and non-hormonal
contraceptive groups, with statistical significance set at p ≤ 0.05.
RESULTS
The 20% response rate was achieved for each sport, with 177
athletes responding to the survey. Respondent characteristics are
presented in Table 1. One third of respondents (n = 58) were
currently using a HC at the time of survey completion. Most
respondents were participating in 4–7 h (n = 91, 51%) or 8–12 h
(n= 61, 34%) of field-based training, and 1–3 h (n= 82, 46%) or
4–7 h (n= 87, 49%) of gym-based training per week.
The types of HC used and the specific types of OC used are
presented in Figure 1. The majority of players using OC could
not identify the type of pill used (i.e., monophasic, triphasic,
n = 42, 89% of OC users). Of those who could not identify the
type, 10 (21% of OC users) were also unable to identify the brand
of OC pill used. HC use for greater than 5 years accounted for
the largest group of users (n = 22, 38%), while 13 (22%) had
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used their current HC method for 12 months or less. Reasons for
using a hormonal contraceptive included: to avoid pregnancy; to
control/regulate their cycle; and to reduce menstrual-related pain
TABLE 1 | Participant characteristics of HC and non-HC users. Data presented








Age (y) 24.9 (5.2) 24.3 (7.2) 24.5 (5.2)
Height (m) 1.68 (0.06) 1.71 (0.32)* 1.70 (0.07)
Mass (kg) 71.5 (12.5) 71.0 (15.7) 71.1 (11.6)
Sport (n; %)a
Rugby League 17; 35% 32; 65%* 49; 24%
Rugby Union/Sevens 22; 46% 26; 54% 48; 24%
Australian Football 19; 24% 61; 76%* 80; 39%
Age at menarche (n; %)b
11 years or younger 9; 16% 13; 11% 22; 12%
12–14 years 34; 59% 77; 65% 111; 63%
15 years or older 15; 26% 26; 22% 41; 23%
Don’t remember 0; 0% 3; 3% 3; 2%
Duration competing at current level (n, %)b
0–2 years 28; 48% 60; 50% 88; 50%
2–4 years 21; 36% 39; 33% 60; 34%
4–6 years 5; 9% 9; 8% 14; 8%
>6 years 5; 9% 17; 14%* 22; 12%
aPercentage represented from total within each specific sport.
bPercentage represented from total within hormonal contraceptive use category.
HC, hormonal contraceptive.
*Significant difference between HC and non-HC groups; p < 0.05.
(Figure 2A). Most users (n = 23, 40%) reported experiencing no
side effects of using a HC, while light or no periods (n = 18),
mood fluctuations (n = 13), and weight gain (n = 10) were the
most commonly reported side effects for others.
Previous use of HC was reported in 73 (41%) respondents,
across Australian football (n= 33), rugby union/sevens (n= 22),
and rugby league (n = 18). Fifty-seven of these respondents no
longer use any HC, while 16 replaced their previous HC use with
a different HC type. Of those who changed HC, eight changed
from one OC to another (often with time between use), three
changed from anOC to a hormonal intrauterine device, two from
an OC to an implant, two from an implant to an OC, and one
from an implant to a hormonal intrauterine device.
The types of HC previously used and the specific types
of OC are presented in Figure 3. The reasons for no longer
using this form of contraception are presented in Figure 2B.
The 57 respondents who previously used a HC, but no
longer do, are made up of athletes from Australian football
(n = 29), rugby union/sevens (n = 15), and rugby league
(n = 13). Negative side effects (n = 23) was the main
reason for discontinuation, including mood swings, weight gain,
depression/anxiety, and headaches/migraines. Eleven individuals
cited that it was no longer needed, however, only five
specified the reason why—minimal sexual activity (n =
2), acne under control (n = 2), and sexual orientation
(n = 1). Mean duration of previous HC use was 3.5 ±
3.3 years.
Across all respondents, only nine athletes reported not
experiencing any pre-menstrual symptoms, of which three were
HC users. For the remaining respondents, a mean of 6 ±
4 different symptoms were reported, with the most common
FIGURE 1 | Distribution of type of hormonal contraceptive use (n = 58) (A) and specific type of oral contraception used (n = 47) (B) among respondents. Gray bars in
panel B indicate an initial response of “Unknown,” of which some responses were subsequently able to be classified by researchers based on identification of specific
brand used.
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FIGURE 2 | Percentage respondents for (A) reasons for hormonal contraception use in current users (n = 58), and (B) reasons for no longer taking a previous form of
hormonal contraception (n = 73). Participants were able to select all reasons that apply for current use, while reasons for no longer using was an open-ended
question that was subsequently grouped by theme.
symptoms being stomach cramps (n = 116) and changes in
mood (n = 100). There was no statistical difference (p >
0.05) in the number of symptoms experienced by HC users
and non-users. Overall, use of medication to treat menstrual-
related symptoms was reported by 69 athletes (32%), while five
athletes chose not to respond. While not statistically different,
within hormonal contraceptive users, 20 (34%) required the
use of medication to alleviate menstrual-related symptoms,
compared to 49 (41%) of non-HC users. Due to menstrual
related symptoms, training was missed (n = 31, 18%) or had
to be adapted (n = 56, 32%) by athletes typically 1–5 times per
year. The number of athletes who reported missing training or
competition due to menstrual related symptoms was similar in
HC (n = 9, 16%) and non-HC users (n = 22, 18%), as was
the need to adapt training (HC users, n = 15, 26%; non-HC
users, n= 41, 34%).
DISCUSSION
Approximately one third of athletes from the three codes of
football in Australia currently use a form of HC, most commonly
a monophasic OC pill. However, almost 90% of OC users
could not identify the specific type that they use. The most
common reasons for use of HC were (1) to prevent pregnancy,
(2) to control their cycle, and (3) to reduce menstrual-related
pain. There was no difference between HC users and non-
users in relation to menstrual symptoms experienced, use of
medication, and the need to adapt or miss training due to their
menstrual cycle.
This study observed a lower HC use among elite female
football athletes—approximately one third (32.7%)—compared
to research conducted in recreational to elite Australian athletes
(42%, Armour et al., 2020) and elite Australian (47%, Larsen
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FIGURE 3 | Distribution of previously used hormonal contraceptive type (n = 73) (A) and specific type of oral contraception used (n = 63) (B) among respondents.
Gray bars in panel B indicate an initial response of “Unknown,” of which some responses were subsequently able to be classified by researchers based on
identification of specific brand used.
et al., 2020), British (50%, Martin et al., 2018), and Danish (57%,
Oxfeldt et al., 2020) athletes across both team and individual
sports. Given a limited amount of research has investigated
menstrual cycle and HC use in team sport athletes, it is unknown
whether the lower prevalence of HC use in the current study is
sport related, or a result of sociocultural, geographical, or other
influencing factors. Given several athletes in this cohort have
previously used an HC, and the second most common reason
for discontinuation was that they wanted to take a “natural”
approach, understanding the changing attitudes toward the use
of HC may be an important consideration. There is a growing
body of literature to suggest negative effects such as depression
(Anderl et al., 2020), poorer bone mineral density (Allaway et al.,
2020), and greater oxidative stress (Cauci et al., 2016) with HC
use. However, these effects may be specific to the HC type,
with OC the main focus of research looking at these such side
effects. The use of HC also masks the natural fluctuations in
endogenous hormones, limiting the ability to use the menstrual
cycle as an indicator of general health (Harber, 2011). Further,
for those athletes who choose to discontinue HC use, it is
important for both athletes and their coaching staff to recognize
that menstrual disturbances may be present for up to 9 months
following cessation (Gnoth et al., 2002). Assessment of athletes’
perceptions of HC use for health and performance reasons
would be beneficial to understanding the factors contributing to
HC use and disuse. Understanding where athlete’s source their
information regarding this choice and the specific experiences
of athletes as they transition away from HC use may also be
beneficial to enable the optimal management of female athletes.
Many of the athletes surveyed were unable to specify the
type or brand of OC they used, suggesting either a lack of
interest in, or awareness of, the different types and/or benefits
and risks of OC use. Research in Australian athletes has suggested
a poor knowledge in relation to the menstrual cycle and use
of HC (Larsen et al., 2020). Greater education may be needed
for athletes to make informed choices about their HC use,
in conjunction with their medical doctor, to ensure optimal
health, well-being, and performance. It is important that athletes
understand that an individual approach to choosing a HC is
required and they are not guided by other teammates or team
coaches, given each has a unique experience with HC and their
menstrual cycle.
We did not observe any differences between HC users and
non-users in relation to experiencing various menstrual-related
symptoms (with both groups reporting stomach cramps and
changes in mood as the most common symptoms), the need
to use medication, or having to adapt training due to these
symptoms. This is despite reasons for using HC including
symptom management and reducing menstrual pain. Reported
negative symptoms are also similar between HC users and
non-users in elite Danish athletes, whereas positive symptoms
were reported more frequently in non-HC users (Oxfeldt et al.,
2020). However, this research only asked to identify the types
of symptoms experienced, rather than rate their severity or
duration. We speculate that it is possible that while HC users
still experience these symptoms, the severity or duration may
be lower than compared to what they would experience if they
were not using a HC. Alternatively, HC have been associated
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with greater inflammation and oxidative stress (Cauci et al.,
2016), which may exacerbate pre-menstrual symptoms in some
individuals. Further research that looks at both endogenous and
exogenous hormones during HC use may help gain further
insight in understanding the etiology of symptom manifestation.
This research is the first to look at athletes’ experiences
and reasons for HC use and disuse in elite football codes in
Australia. With the growing professionalism for women’s teams
within these codes, understanding this information is important
to assist with the management of athletes’ health and well-
being. However, it is important to recognize that these findings
are specific to this population group, and other elite women’s
team sports may have different findings specific to their sport
or geographic location, based on different medical advice or
personal preferences. The ∼20% response rate (based on the
estimated total population size)may also limit the generalizability
of these findings, hence further work is required to corroborate
these findings. Participants’ involvement in this study may also
be influenced by self-selection bias. Consequently, participants
who completed the study may have already been interested in, or
aware of, how menstrual cycle and HC use interacts with their
health, training, and performance. Additionally, this research
focused on elite players, however, the practices of athletes
competing in sub-elite, youth, and recreational competitions
may be more diverse due to a different emphasis on general
health vs. performance, or based on the resources available
to them within their sporting environment. Determining what
factors contribute to athletes deciding to use (or stop using)
HC, and the specific types and formulations, is an important
avenue for future research in female athletes. Understanding the
transition between exogenous (HC use) and natural hormones
stabilizing following HC discontinuation, and the subsequent
influence on menstrual-related symptoms and performance
is also an important consideration for practitioners and the
need for individualized athlete management. This will ensure
sporting bodies and associated medical professionals are able
to specifically target the education and management practices
for female athletes. Whether an athlete’s decision is based
on health, practicality, science, or sociological influences (e.g.,
friend/teammate recommendations or experiences) is yet to
be examined. This may be important when it comes to how
information is received and acted on by athletes, and how
sporting clubs can play their role to optimize the health,
performance, and well-being of athletes.
Overall, we make three recommendations from this research.
First, there is a need for greater education about the menstrual
cycle and HC options for athletes. Second, this education should
extend to coaches, support staff, and clinicians to ensure the
optimal management of female athletes’ health and performance.
Given Australian athletes do not often discuss their menstrual
cycle or related symptoms with coaching staff (Armour et al.,
2020), empowering coaches with this knowledge may help
to remove any perceived barriers to having these important
conversations. Third, further research is required to understand
in greater detail the HC experiences of athletes, how HC use
influences the performance and recovery of athletes, and explore
alternative methods to HC for the management of MC symptoms
without negative side effects.
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